Facing the "Irreversible" Challenge of Cartilage Repair, Ningjiao Biotech Offers a "Triple Biomimetic" Solution

The knee joint is the most frequently used and weight-bearing joint in the human body, making cartilage damage a common yet long-standing clinical issue lacking effective solutions. Sports injuries, trauma, and age-related degeneration all continuously accelerate the wear and tear of articular cartilage.

From the perspective of tissue structure, articular cartilage is only about 3–4 millimeters thick and lacks blood vessels, nerves, and lymphatic tissues. It primarily relies on synovial fluid for nutrient exchange. This structural characteristic makes it extremely difficult for the human body to repair cartilage once it is damaged.

Knee joint cartilage is a one-time consumable. In daily life and work, any routine activity puts varying degrees of pressure on our knee joints, causing wear and tear. Image from the internet.

In clinical practice, cartilage injuries often present with symptoms such as knee pain, swelling, and limited mobility, significantly impacting the patient's quality of life. Without timely and effective intervention, some patients may further develop osteoarthritis, ultimately leading to joint replacement.

However, there are still significant limitations in existing treatment methods. Traditional microfracture or debridement procedures mostly result in "fibrocartilage" with poor wear resistance, making it difficult to truly restore joint function. Meanwhile, high-end cartilage repair products in the international market are generally expensive, with treatment costs often reaching tens of thousands of dollars, causing many patients to miss the window for early intervention. How to strike a balance between repair effectiveness and accessibility has become a core issue亟待破解 in the field of cartilage repair.

Against this backdrop, exploration around "in-situ regeneration of transparent cartilage" has begun to attract attention. Recently, VCBeat learned that,Chongqing Ningjiao Biotechnology Co., Ltd. (hereinafter referred to as "Ningjiao Biotech") is advancing a cartilage regeneration and repair product based on the concept of "structural, compositional, and functional tri-biomimicry" — the Cartilage Biomimetic Matrix Gel. This product aims to reconstruct the microenvironment required for cartilage regeneration, inducing endogenous cells to participate in the repair process, offering a technical approach distinct from traditional "fill-and-patch" methods for cartilage injuries.

In the view of Ningjiao Biotech, a truly effective cartilage repair material should not merely be a filler that fills defects but rather a bioinductive scaffold capable of actively participating in tissue regeneration and guiding cell behavior. Following this concept, its cartilage biomimetic matrix gel is designed as a biomimetic system that can reconstruct the microenvironment for cartilage regeneration, primarily used for the regenerative repair of focal articular cartilage defects.

This product can induce mesenchymal stem cells in the joint cavity and chondrocytes around the defect to adhere to the material, and proliferate and differentiate under the influence of the joint cavity microenvironment, thereby regenerating and repairing cartilage defects.

From an overall design perspective, the core advantages of this product can be summarized as "components, structure, and function" in three aspects of bionic synergy.

At the component level, Ningjiao Bio selects type II collagen derived from porcine knee cartilage, combined with chondroitin sulfate and hyaluronic acid, highly restoring the biochemical composition of natural cartilage.Compared with similar materials on the market that are mainly composed of Type I collagen,Type II collagen is closer to the native components of cartilage, more conducive to maintaining the stable phenotype of chondrocytes, and reducing the risk of fibrotic tissue formation during the repair process.

At the structural level, the gel simulates the "solid-liquid biphasic" micro-morphology of natural cartilage, forming a three-dimensional network structure similar to a sponge, providing stable physical support for cell migration, nutrient exchange, and metabolic waste excretion.This structural design makes the material itself not only a carrier but also a "microenvironment regulator" during the regeneration process.

At the functional level, the cartilage bionic matrix gel does not rely on exogenous cell transplantation but induces synovial-derived mesenchymal stem cells to migrate to the defect area and differentiate by reconstructing local regenerative conditions, thereby forming transparent cartilage that is closer to natural tissue in situ.Rather than fibrocartilage with limited mechanical properties.

Preclinical Large Animal Trials of Cartilage Biomimetic Matrix Gel Products

Building on the aforementioned biomimetic design, Ningjiao Bio further innovated the gelation mechanism, balancing regenerative effects with the safety and convenience of clinical operations.The product adopts the Schiff base reaction gelation mechanism,By gently chemically modifying hyaluronic acid and chondroitin sulfate to react in situ with the amino groups on the surface of type II collagen.The entire reaction process does not require the introduction of exogenous chemical cross-linking agents, with water as the only byproduct, significantly reducing the potential risk of biotoxicity.

In clinical applications, the material maintains good fluidity before injection and can be injected into the defect area through a minimally invasive approach under arthroscopy. It fully fills cartilage defects of different shapes and completes in-situ curing within minutes. This "one-time injection, instant repair" mode not only makes it easy for doctors to quickly adapt but also shortens operation time, laying the foundation for the widespread application of future products.

After completing key validations at the technical level, Ningjiao Bio is gradually shifting its focus to clinical translation and scale-up preparation.

It is reported that,The company has now completed the construction of the pilot plant and carried out dozens of clinical exploratory studies, with a follow-up time of up to 3 years. Preliminary results show that patients' pain symptoms were significantly relieved, joint mobility improved, and signs of cartilage regeneration were observed in some cases around six months.Laid the foundation for subsequent larger-scale clinical validation.

While advancing the clinical pathway for its products, Ningjiao Biotech has also begun to consider the sustainable development model for cartilage regeneration materials from an industry perspective. Focusing on porcine knee cartilage, a key upstream raw material, the company is in communication with local governments to explore an industrial synergy pathway that spans from standardized raw material collection and high-value extraction to applications in regenerative medicine.

Ningjiao Biotech believes that the industrialization of cartilage bionic materials relies not only on breakthroughs in single-point technologies but also on the systematic construction of raw material systems, quality control, and production capabilities. By collaborating with local industrial systems, the company aims to ensure the safety, stability, and traceability of raw materials while promoting the upgrading of related biomaterials toward higher value-added applications. At the same time, it seeks to foster new growth opportunities for regional biopharmaceutical industries.

Currently,The company has initiated a new round of financing to advance multi-center clinical trials, registration applications, and production line establishment.Promote the early benefit of Chinese-produced cartilage regeneration and repair solutions for patient groups.